Genprex's nanovesicle therapies target key oncogenic pathways in cancer cells, inducing programmed cell death and controlling cell signaling and inflammatory pathways. These therapies can be used in combination with other targeted treatments to overcome genomic limitations and reduce drug resistance. Genprex aims to address the unmet medical needs of cancer patients and expand the population benefiting from combination treatments. Additionally, the company focuses on developing gene therapies for patients with diabetes. Genprex collaborates with world-class institutions and has a multidisciplinary team with expertise in the biotech and pharmaceutical industries.